GSK will provide all required doses of niraparib for the study. Credit: GSK.

Zentalis Pharmaceuticals has announced a clinical collaboration agreement to evaluate the combination of its ZN-c3 and GlaxoSmithKline’s (GSK) ZEJULA (niraparib) in advanced epithelial ovarian cancer patients.

ZEJULA is an FDA and EMA-approved oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

At present, Zentalis is conducting clinical studies with its oral WEE1 inhibitor product candidate, ZN-c3, as a monotherapy and in combination with certain standard of care therapies.

Zentalis Pharmaceuticals chairman and CEO Dr Anthony Sun said: “This clinical collaboration and supply agreement with GSK allows us to investigate the broader potential of our WEE1 inhibitor when used as part of a combination treatment with niraparib, a PARP inhibitor.

“As demonstrated in our preclinical studies, ZN-c3 is designed to have significant advantages over other investigational WEE1 inhibitor therapies. We believe this combination has the potential to meaningfully improve the outcomes for patients with ovarian cancer.”

Under the non-exclusive collaboration terms, Zentalis will perform the study with GSK providing all required doses of niraparib. Complete ownership of ZN-c3 would be maintained by Zentalis.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

WEE1 plays a key role in cellular regulation and repair and its inhibition causes dysregulation of DNA replication and subsequently induces apoptosis.

Based on these complementary mechanisms of action, the use of WEE1 and PARP inhibitors is expected to potentially have synergistic anti-tumour activity.

Zentalis is currently conducting a Phase I/II clinical trial of ZN-c3 in patients with advanced solid tumours and a Phase Ib trial evaluating ZN-c3 in combination with chemotherapy in advanced ovarian cancer patients.

The company also plans to initiate a Phase I/II trial in combination with GSK’s niraparib for advanced ovarian cancer patients.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact